Osteoprotegerin and TRAIL in Acute Onset of Atrial Fibrillation.
BACKGROUND
There is a growing amount of evidence that inflammatory processes are involved in the development of atrial fibrillation (AF) and its complications. We decided to investigate the behavior of osteoprotegerin (OPG) and TNF-related apoptosis inducing ligand (TRAIL) in terms of acute onset of AF.


RESULTS
We included 60 patients with acute onset of AF, candidates for pharmacological cardioversion. The presence of cardiovascular comorbidities was connected with higher concentration of OPG and lower level of TRAIL right from the first hours of AF paroxysm. The initial TRAIL level correlated also positively with left ventricle ejection fraction and negatively with left atrium diameter. We found subsequent increase of OPG in subgroups selected on the basis of CHA2DS2-VASc scoring. Although basal concentrations of studied markers did not allow prediction of the restoration of sinus rhythm, we observed important increase of TRAIL concentration in subgroup with sinus rhythm maintenance (94.11 ± 29.46 versus 111.39 ± 30.23 pg/mL; p = 0.002).


CONCLUSIONS
OPG and TRAIL are associated with the underlying cardiovascular damage in AF, but their balance is modulated by the fact of sinus rhythm restoration. Determining the suitability of OPG and TRAIL as predictive markers in AF requires further prospective studies.
Chair of Internal Medicine and Gerontology, Jagiellonian University Medical College, Ulica Śniadeckich 10, 31-531 Kraków, Poland.
Krzysztof
K
Rewiuk
Chair of Internal Medicine and Gerontology, Jagiellonian University Medical College, Ulica Śniadeckich 10, 31-531 Kraków, Poland.
Tomasz
T
Grodzicki
D000208:Acute Disease; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D001281:Atrial Fibrillation / Q000097:blood* / Q000209:etiology / Q000628:therapy; D015415:Biomarkers / Q000097:blood; D002097:C-Reactive Protein / Q000378:metabolism; D002784:Cholesterol / Q000097:blood; D004554:Electric Countershock; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D053244:Osteoprotegerin / Q000097:blood*; D011446:Prospective Studies; D053221:TNF-Related Apoptosis-Inducing Ligand / Q000097:blood*; D016896:Treatment Outcome
D015415:Biomarkers; D053244:Osteoprotegerin; D053221:TNF-Related Apoptosis-Inducing Ligand; C506030:TNFRSF11B protein, human; C505653:TNFSF10 protein, human; D002097:C-Reactive Protein; D002784:Cholesterol